NCT07075224已完成1 期
Pharmacodynamics of Investigational Medicinal Product (IMP) 08P2002F0 (Fixed Dose Combination of 0.34 % Tropicamide and 2.5 % Phenylephrine Hydrochloride, Eye Drop Solution), a New Ophthalmic Mydriatic Solution in Healthy Volunteers
Unither Pharmaceuticals, France4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2025年11月1日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Change in pupil diameter at 60 minutes from the time of first dose versus baseline, as measured with photo (central reading)
研究概览
简要总结
The objective of this study is to explore pharmacodynamic effects and safety of IMP 08P2002F0 for dilation of the pupil, a solution combining two mydriatic agents tropicamide and phenylephrine hydrochloride at the concentrations of 0.34% and 2.5% respectively, versus Mydriasert®
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Diagnostic
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers of both genders, aged ≥18 at the time of signing the informed consent.
- •Healthy volunteers are declared healthy based on medical history, physical examination, ophthalmological examination, Electrocardiogram (ECG), within the stated normal range; a participant with a clinical abnormality or laboratory parameter(s) outside the reference range may be included if the investigator agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures or interpretation..
- •3. Females who participate in the study, that are at reproductive age agree to undergo pregnancy tests and to use a highly effective birth control method during the study.
排除标准
- •Hypersensitivity to the active substances or to the excipients or related class of the medicinal product. Serious hypersensitivity reactions include angioedema, anaphylaxis and exfoliative skin conditions including Stevens-Johnson syndrome.
- •Clinically significant illness or surgery within four weeks prior IMP administration.
- •Clinically significant ECG abnormalities or vital sign abnormalities (seated systolic blood pressure < 90 or >140 mmHg, seated diastolic blood pressure < 50 or > 90 mmHg or heart rate less than 50 or over 100 bpm) at screening.
- •History or presence of any clinically significant cardiovascular, pulmonary, hepatobiliary, renal, haematological, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, malignant disease or eye disorders as glaucoma or a family history of glaucoma.
- •Clinically significant abnormal laboratory values.
- •Unwilling to discontinue use of contact lenses on the day of a treatment visit.
- •Current active eye disease (i.e. any disease for which topical or systemic ophthalmic medication is necessary). In case of historical eye disease, topical or systemic ophthalmic medication should have been stopped for at least one month before the study.
- •Pupillary abnormalities (irregular, very dark iris, iris synechiae, eye movement disorder (e.g. Nystagmus, etc.), dacryocystitis and all other pathologies of tears drainage system.
- •Use of any ophthalmic medication except unpreserved artificial tears on the day of a treatment visit.
- •History of inflammatory ocular disease (e.g. iritis, uveitis, herpetic keratitis).
- •History of ocular trauma, infection or inflammation within the last 3 months.
- •Ocular surgery or laser treatment of any kind in the study eye within 3 months.
- •Irregularly-shaped pupil secondary to ocular trauma, intraocular surgery or congenital defect.
- •History of neurogenic pupil disorder (e.g. Horner's syndrome, third cranial nerve palsy, Adie's pupil, Argyl Robertson syndrome, etc.).
- •History of iris surgery of any kind (e.g. iridotomy, iridectomy, coreoplasty).
- •History of previous corneal surgery; iris atrophy, traumatic mydriasis or angle recession, chronic or acute uveitis.
- •Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration and superficial punctuate keratitis).
- •Pseudoexfoliation, exfoliative syndrome.
- •History of closed-angle glaucoma.
- •Subjects with narrow angle prone to glaucoma precipitated by mydriatics
- •Subject undergoing treatment identified as potentially interacting with the IMP, including antidepressant drugs, beta-blockers, other indirect sympathomimetics, alpha sympathomimetics (oral and/or nasal routes), dopaminergic ergot alkaloids, ergot alkaloid vasoconstrictors, selective MAOI-A, linezolid, and halogenated volatile anesthetics.
- •. Subject planning to receive an MAOI within 3 weeks following the end of the study.
- •Subjects who have received non-selective monoamine oxidase inhibitors (MAOIs) within the last 15 days
结局指标
主要结局
Change in pupil diameter at 60 minutes from the time of first dose versus baseline, as measured with photo (central reading)
时间窗: 60 minutes
次要结局
- Time to obtain sufficient mydriasis(6 hours post dose)
- Proportion of eyes achieving pupil diameter of 6.0 mm or greater(Throughout the 6 hours, at 30 minutes, at 1 hour and 2 hours.)
- Proportion of eyes achieving pupil diameter of 7.0 mm(Throughout the 6 hours, at 30 minutes, at 1 hour and 2 hours.)
- Time from baseline to maximal pupil dilation(6 hours post dose)
- Change in pupil diameter at other timepoints(At 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 1 hour and 15 minutes, 1 hour and 30 minutes, 2 hours, 2 hours and 30 minutes, 3 hours, 3 hours and 30 minutes, 4 hours, 4 hours and 30 minutes, 5 hours, 6 hours.)
- Pupil size(At 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 1 hour and 15 minutes, 1 hour and 30 minutes, 2 hours, 2 hours and 30 minutes, 3 hours, 3 hours and 30 minutes, 4 hours, 4 hours and 30 minutes, 5 hours, 6 hours.)
- Distribution of pupil diameters(At 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, 1 hour and 15 minutes, 1 hour and 30 minutes, 2 hours, 2 hours and 30 minutes, 3 hours, 3 hours and 30 minutes, 4 hours, 4 hours and 30 minutes, 5 hours, 6 hours)
- Subject ocular discomfort(At 10 minutes, 30 minutes, 60 minutes, 1 hour and 30 minutes, 2 hours, and 6 hours post-administration.)
- Percent of Subjects' Study Eyes with Pupil Diameter Returning to Baseline(Throughout the 6 hours, at 3 hours, 4 hours, 5 hours, 6 hours.)
- Percentage of subjects' study eyes returning to less than or equal to 0.2 mm from baseline pupil diameter(Throughout the 6 hours, at 3 hours, 4 hours, 5 hours, 6 hours.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy SubjectsType 2 DiabetesNCT01135446AstraZeneca35
已完成
1 期
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus PatientsType 2 Diabetes MellitusNCT02346175Jiangsu HengRui Medicine Co., Ltd.30
招募中
1 期
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT04494503Ascentage Pharma Group Inc.123
已完成
1 期
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain LesionsHealthy VolunteersBrain LesionNCT03603106Guerbet142
已完成
2 期
Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia BHemophilia BNCT00768287Medexus Pharma, Inc.77